Anti-IgE therapy markedly reduces both airway inflammation and mast cell activation, as manifested by reduced IL-4 expression, but has a minimal effect on BHR: this suggests that other factors are causally linked to airway hyperresponsiveness to methacholine in asthma [111]. Here, IGHE is linked to asthma.